Segment Data (Tables)

6 Months Ended

Jul. 01, 2022

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:


	Successor		Predecessor

	Period from June 17, 2022 through July 1, 2022		Period from April 2, 2022 through June 16, 2022		Three Months Ended June 25, 2021
Net sales:
Specialty Brands	$	58.2	$	247.7	$	381.5
Specialty Generics	26.8		136.0		164.9
Net sales	$	85.0	$	383.7	$	546.4
Operating income (loss):
Specialty Brands	$	4.5	$	102.4	$	186.6
Specialty Generics (1)	0.3		30.9		26.9
Segment operating income	4.8		133.3		213.5
Unallocated amounts:
Corporate and unallocated expenses (2)	(0.9)		(15.4)		(25.7)
Depreciation and amortization	(48.4)		(144.6)		(168.1)
Share-based compensation	—		(0.5)		(2.4)
Restructuring charges, net	(1.1)		(2.8)		(6.1)

Separation costs (3)	(9.2)		(7.0)		(0.3)



Operating (loss) income	$	(54.8)	$	(37.0)	$	10.9

(1)Includes $2.4 million of fresh-start inventory-related expense during the period from June 17, 2022 through July 1, 2022 resulting from the Company's change in accounting estimate as disclosed in Note 1.

(2)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(3)Represents costs included in selling, general and administrative expenses, primarily related to expenses incurred related to the Predecessor directors and officers' policy and severance for the former CEO of the Predecessor, in addition to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.


	Successor		Predecessor
	Period from June 17, 2022 through July 1, 2022		Period from January 1, 2022 through June 16, 2022		Six Months Ended June 25, 2021
Net sales:
Specialty Brands	$	58.2	$	587.1	$	789.9
Specialty Generics	26.8		287.5		314.5
Net sales	$	85.0	$	874.6	$	1,104.4
Operating income (loss):
Specialty Brands	$	4.5	$	267.2	$	398.7
Specialty Generics (1)	0.3		65.3		58.6
Segment operating income	4.8		332.5		457.3
Unallocated amounts:
Corporate and unallocated expenses (2)	(0.9)		(48.2)		(48.3)
Depreciation and amortization	(48.4)		(321.8)		(337.7)
Share-based compensation	—		(1.7)		(6.0)
Restructuring charges, net	(1.1)		(9.6)		(6.5)
Non-restructuring impairment charges	—		—		(64.5)
Separation costs (3)	(9.2)		(9.0)		(0.9)



Operating loss	$	(54.8)	$	(57.8)	$	(6.6)

(2)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:


	Successor		Predecessor

	Period from June 17, 2022 through July 1, 2022		Period from April 2, 2022 through June 16, 2022		Three Months Ended June 25, 2021
Acthar Gel	$	27.5	$	94.2	$	151.5
INOmax	13.5		66.8		105.9
Ofirmev	(0.2)		(0.1)		6.5
Therakos	10.2		49.7		68.5
Amitiza (1)	5.8		33.8		44.8
Other	1.4		3.3		4.3
Specialty Brands	58.2		247.7		381.5

Opioids	8.7		38.8		53.8
ADHD	1.8		6.8		7.8
Addiction treatment	2.5		14.1		16.0
Other	0.1		2.0		3.6
Generics	13.1		61.7		81.2
Controlled substances	1.7		17.2		25.6
APAP	11.3		50.2		51.7
Other	0.7		6.9		6.4
API	13.7		74.3		83.7
Specialty Generics	26.8		136.0		164.9
Net sales	$	85.0	$	383.7	$	546.4

(1)Amitiza consists of both product net sales and royalties. Refer to Note 4 for further details on Amitiza's revenues.


	Successor		Predecessor
	Period from June 17, 2022 through July 1, 2022		Period from January 1, 2022 through June 16, 2022		Six Months Ended June 25, 2021
Acthar Gel	$	27.5	$	221.9	$	280.5
INOmax	13.5		165.8		239.9
Ofirmev	(0.2)		2.5		19.3
Therakos	10.2		109.6		135.3
Amitiza (1)	5.8		81.5		106.2
Other	1.4		5.8		8.7
Specialty Brands	58.2		587.1		789.9

Opioids	8.7		88.8		108.5
ADHD	1.8		17.5		16.1
Addiction treatment	2.5		30.0		32.4
Other	0.1		4.9		5.5
Generics	13.1		141.2		162.5
Controlled substances	1.7		37.6		43.0
APAP	11.3		96.5		97.2
Other	0.7		12.2		11.8
API	13.7		146.3		152.0
Specialty Generics	26.8		287.5		314.5
Net sales	$	85.0	$	874.6	$	1,104.4

(1)Amitiza consists of both product net sales and royalties. Refer to Note 4 for further details on Amitiza's revenues.